Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you consider using IO alone for lung cancer patients who are PDL1 <1 but have high TMB?
Related Questions
How would you treat patients with limited-stage small cell lung cancer who have short term contraindications for systemic chemotherapy?
How would you approach a patient with limited stage SCLC who progressed immediately after completing chemoradiation with brain metastasis?
Do you think it's appropriate to run separate NGS panels on biopsies from lesions in both the right and left lung in a patient suspected of two lung primaries?
What is your approach to obtain tissue diagnosis for a patient with a lung primary and spine metastasis?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
What chemotherapy regimens would be appropriate for cisplatin-ineligible patients to receive concurrently with definitive radiotherapy for locally advanced (inoperable) thymic carcinoma?
How are you approaching patients who receive neoadjuvant chemo immunotherapy for resectable NSCLC who after completion of neoadjuvant treatment are no longer surgical candidates due to factors such as toxicity, decline in PS, or patient preference?
Is there a role for pemetrexed in the treatment of metastatic adenosquamous NSCLC?
How would you manage a patient with stage IV EGFR L858R mutation but with a debilitating drug rash from osimertinib?
Would you consider using trastuzumab deruxtecan in HER2-low expressing NSCLC based on data from breast cancer?
